Eyebiotech Limited (EyeBio) is a clinical-stage biotechnology company specializing in ophthalmology, focused on developing therapies to protect, restore, and improve vision in patients with sight-threatening retinal diseases such as diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD), and retinal vein occlusion.
Founded in 2021 with operations in the US and UK, EyeBio was acquired by Merck in 2024 and now operates as a wholly-owned subsidiary. Its pipeline features innovative biologics targeting retinal vascular leakage, including lead candidate Restoret (MK-3000/EYE103), a tetravalent tri-specific Wnt pathway agonist in Phase 2b/3 trials (e.g., BRUNELLO for DME). Another key asset is Tiespectus (MK-8748/EYE201), a bispecific Tie2 agonist/VEGF inhibitor in Phase 1/2a (e.g., RIOJA, MALBEC) for NVAMD and other indications, with pivotal trials planned.
None yet. When a new project in the record names EyeBio as owner, partner or investor, it shows here.
Remigromig met non-inferiority for mean BCVA change versus monthly ranibizumab at one year in DME; higher rates of PDR-related adverse events and discontinuations were reported.
Tri-specific Wnt-pathway agonist showed non-inferior BCVA gains vs ranibizumab at week 52; higher rates of PDR, vitreous hemorrhage and discontinuations observed.
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
Pivotal Phase 2b/3 MALBEC trial begins for a bispecific Tie2 agonist/VEGF inhibitor in neovascular AMD; randomized vs aflibercept, primary endpoint mean BCVA change at Year 1.
